Get E&O weekly. | Subscribe
Digital health research from Brian Dolan.
Welcome to E&O.
Last week I shared new financial details surrounding three recent M&A deals. Next week I'll write Part II of how a piece of software gets coded like a drug. Here's what's happening this week:
- After a presentation on digital health business models to 100+ health startups in Finland, Sweden, and Iceland, I spent the rest of this week trying to wrap my head around NDC vs UDI coding. Read Part I: How Welldoc got an NDC code -- after the jump.
- One of the newer prescription digital therapeutics companies I've been tracking (Issue 035) is IBS-focused Mahana Therapeutics. A new Medium post from the company reveals that Mahana's first product will be named Parallel: "Together, we’ve made major strides in a short amount of time. This includes the development of Parallel, Mahana’s first product,